Molecular structure of Maytansine, CAS Number: 35846-53-8
Maytansine (CAS 35846-53-8)
CAS Number:
35846-53-8
Molecular Weight:
692.2
Molecular Formula:
C34H46ClN3O10
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Maytansine (CAS 35846-53-8) References
- Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. | Lopus, M., et al. 2010. Mol Cancer Ther. 9: 2689-99. PMID: 20937594
- Site-specific antibody drug conjugates for cancer therapy. | Panowski, S., et al. 2014. MAbs. 6: 34-45. PMID: 24423619
- Trastuzumab emtansine: mechanisms of action and drug resistance. | Barok, M., et al. 2014. Breast Cancer Res. 16: 209. PMID: 24887180
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. | Li, JY., et al. 2016. Cancer Cell. 29: 117-29. PMID: 26766593
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. | von Minckwitz, G., et al. 2019. N Engl J Med. 380: 617-628. PMID: 30516102
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. | Rinnerthaler, G., et al. 2019. Int J Mol Sci. 20: PMID: 30841523
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. | Moore, KN., et al. 2021. Ann Oncol. 32: 757-765. PMID: 33667670
- Biomimetic Nanoerythrosome-Coated Aptamer-DNA Tetrahedron/Maytansine Conjugates: pH-Responsive and Targeted Cytotoxicity for HER2-Positive Breast Cancer. | Ma, W., et al. 2022. Adv Mater. 34: e2109609. PMID: 35064993
- Targeted delivery of maytansine to liver cancer cells via galactose-modified supramolecular two-dimensional glycomaterial. | Xie, HN., et al. 2022. Chem Commun (Camb). 58: 5029-5032. PMID: 35373789
- New insights into the anticancer therapeutic potential of maytansine and its derivatives. | Zafar, S., et al. 2023. Biomed Pharmacother. 165: 115039. PMID: 37364476
Inhibitor of:
β5 Tubulin, 4930415F15Rik, 4930415O20Rik, C12orf23, CapG, CCDC62, HOOK1, Katanin p80 B1, KIAA0841, LLC1, MAP-1A, SLAIN2, TBCD, Tektin 4, and Tub.Activator of:
1700019B03Rik, 9530077C05Rik, Dynlt1b, Katanin p60 AL1, KIF4, KIFC1, MARK1, MDM1, pierce 1, SPMIP2, and TTLL11.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Maytansine, 100 mg | sc-507510 | 100 mg | $1000.00 |